Background: Long term follow up of the Optic Neuritis Treatment Trial (ONTT) cohort to evaluate brain magnetic resonance imaging (MRI) in patients who have not developed clinically definite multiple sclerosis. Objecti...Background: Long term follow up of the Optic Neuritis Treatment Trial (ONTT) cohort to evaluate brain magnetic resonance imaging (MRI) in patients who have not developed clinically definite multiple sclerosis. Objective: To determine th e proportion of patients with monosymptomatic optic neuritis who manifest new br ain MRI lesions without having developed clinically definite multiple sclerosis 10 to 14 years after enrollment in the ONTT. Design: Observational study. Settin g: Fourteen clinical centers. Participants: One hundred eight ONTT patients who had not developed clinically definite multiple sclerosis 10 to 14 years after st udy enrollment. Main Outcome Measure: Development of new T2 lesions on follow u p brain MRI. Results: At least 1 T2 lesion 3 mm or larger was observed on follow up MRIs in 27 (44%) of 61 patients with normal baseline MRIs. Additional lesi ons (≥3 mm) were present on follow up MRIs in 26 (74%) of 35 patients with ab normal baseline MRIs. Conclusions: A subset of patients with monosymptomatic opt ic neuritis manifest neither clinical signs nor MRI evidence of demyelination af ter more than 10 years of follow up. In other cases followed up for this length of time, MRI signal abnormalities may accumulate without causing new clinical m anifestations of multiple sclerosis. This information is useful in counseling pa tients who develop first episode optic neuritis.展开更多
Objective: To explore the potential of dexrazoxane to suppress subclinical cardiotoxicity in MS patients receiving mitoxantrone. Methods: An open-label study was performed to evaluate possible subclinical cardiotoxici...Objective: To explore the potential of dexrazoxane to suppress subclinical cardiotoxicity in MS patients receiving mitoxantrone. Methods: An open-label study was performed to evaluate possible subclinical cardiotoxicity in multiple sclerosis patients treated quarterly with mitoxantrone (48mg/m2 cumulative), with and without concomitant dexrazoxane, using blinded serial radionucleide ventriculography. Results: No patient experienced symptoms of heart failure. Patients receiving dexrazoxane, which is cardioprotective for anthracyclines, exhibited a significantly lesser decline in left ventricular ejection fraction (mean change, - 3.80% vs - 8.55% , p < 0.001). Interpretation: These results support a cardioprotective effect of dexrazoxane in mitoxantrone treated multiple sclerosis patients.展开更多
The role of the neuronal compartment in multiple sclerosis： Multiple sclerosis （MS） is a chronic inflammatory demyelin- ating disease affecting the central nervous system （CNS）. It is usually characterized by ini...The role of the neuronal compartment in multiple sclerosis： Multiple sclerosis （MS） is a chronic inflammatory demyelin- ating disease affecting the central nervous system （CNS）. It is usually characterized by initial relapses and remissions with subsequent progressive neurological deterioration. MS is the most common acquired neurological disorder affecting young adult persons, Considering the early age of onset of the disease and the massive physical and cognitive restrictions patients face as disease progresses, the identification of the cause and the development of therapeutic strategies is of inamense importance.展开更多
A 35-year-old woman with a history of indeterminate colitis developed symptoms of multiple sclerosis after treatment with infliximab. Neurologic examination confirmed upper and lower extremity motor and sensory defici...A 35-year-old woman with a history of indeterminate colitis developed symptoms of multiple sclerosis after treatment with infliximab. Neurologic examination confirmed upper and lower extremity motor and sensory deficits. MRI showed multiple enhancing white matter lesions distributed throughout her brain as well as her thoracic spine. There may be a link between inflammatory demyelinating disease of the central nervous system and anti-tumor necrosis-αtherapy. This case report describes the onset or worsening of a demyelinating process after the initiation of infliximab therapy in a patient with indeterminate colitis.展开更多
文摘Background: Long term follow up of the Optic Neuritis Treatment Trial (ONTT) cohort to evaluate brain magnetic resonance imaging (MRI) in patients who have not developed clinically definite multiple sclerosis. Objective: To determine th e proportion of patients with monosymptomatic optic neuritis who manifest new br ain MRI lesions without having developed clinically definite multiple sclerosis 10 to 14 years after enrollment in the ONTT. Design: Observational study. Settin g: Fourteen clinical centers. Participants: One hundred eight ONTT patients who had not developed clinically definite multiple sclerosis 10 to 14 years after st udy enrollment. Main Outcome Measure: Development of new T2 lesions on follow u p brain MRI. Results: At least 1 T2 lesion 3 mm or larger was observed on follow up MRIs in 27 (44%) of 61 patients with normal baseline MRIs. Additional lesi ons (≥3 mm) were present on follow up MRIs in 26 (74%) of 35 patients with ab normal baseline MRIs. Conclusions: A subset of patients with monosymptomatic opt ic neuritis manifest neither clinical signs nor MRI evidence of demyelination af ter more than 10 years of follow up. In other cases followed up for this length of time, MRI signal abnormalities may accumulate without causing new clinical m anifestations of multiple sclerosis. This information is useful in counseling pa tients who develop first episode optic neuritis.
文摘Objective: To explore the potential of dexrazoxane to suppress subclinical cardiotoxicity in MS patients receiving mitoxantrone. Methods: An open-label study was performed to evaluate possible subclinical cardiotoxicity in multiple sclerosis patients treated quarterly with mitoxantrone (48mg/m2 cumulative), with and without concomitant dexrazoxane, using blinded serial radionucleide ventriculography. Results: No patient experienced symptoms of heart failure. Patients receiving dexrazoxane, which is cardioprotective for anthracyclines, exhibited a significantly lesser decline in left ventricular ejection fraction (mean change, - 3.80% vs - 8.55% , p < 0.001). Interpretation: These results support a cardioprotective effect of dexrazoxane in mitoxantrone treated multiple sclerosis patients.
文摘The role of the neuronal compartment in multiple sclerosis： Multiple sclerosis （MS） is a chronic inflammatory demyelin- ating disease affecting the central nervous system （CNS）. It is usually characterized by initial relapses and remissions with subsequent progressive neurological deterioration. MS is the most common acquired neurological disorder affecting young adult persons, Considering the early age of onset of the disease and the massive physical and cognitive restrictions patients face as disease progresses, the identification of the cause and the development of therapeutic strategies is of inamense importance.
文摘A 35-year-old woman with a history of indeterminate colitis developed symptoms of multiple sclerosis after treatment with infliximab. Neurologic examination confirmed upper and lower extremity motor and sensory deficits. MRI showed multiple enhancing white matter lesions distributed throughout her brain as well as her thoracic spine. There may be a link between inflammatory demyelinating disease of the central nervous system and anti-tumor necrosis-αtherapy. This case report describes the onset or worsening of a demyelinating process after the initiation of infliximab therapy in a patient with indeterminate colitis.
